In people with pulmonary arterial hypertension (PAH), adding Winrevair (sotatercept-csrk) to standard therapy was linked to longer survival, fewer…
Articles by Patricia Inácio, PhD
People with chronic thromboembolic pulmonary hypertension (CTEPH) continue to experience significant symptoms that interfere with daily life, even…
Having more severe bronchopulmonary dysplasia (BPD) — a chronic lung disease that occurs when a baby’s lungs aren’t fully developed…
A 68-year-old man with severe pulmonary arterial hypertension, or PAH — high blood pressure in the lungs — and…
Treatment with inhaled nitric oxide (iNO) and pulmonary surfactant within the first three days of life significantly reduces the risk…
Ten members of the pulmonary hypertension (PH) community were honored by the Pulmonary Hypertension Association (PHA) for their dedication and…
Health Canada has approved Merck’s Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension (PAH). The approval specifically covers the…
Tenax Therapeutics has raised about $100 million in private funding to help accelerate the clinical development of oral levosimendan…
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to ZM001, a first-in-class investigational antibody from…
Patients with an intermediate to high risk of mortality in the first year following a pulmonary arterial hypertension (PAH)…
High blood levels of resistin, a hormone produced by fat cells, may help identify pulmonary arterial hypertension…
A natural substance isolated from a houseplant shows promise as a potential treatment to prevent and reverse pulmonary hypertension…